PE20030760A1 - Moleculas pequenas para el tratamiento del crecimiento celular anormal - Google Patents
Moleculas pequenas para el tratamiento del crecimiento celular anormalInfo
- Publication number
- PE20030760A1 PE20030760A1 PE2002001190A PE2002001190A PE20030760A1 PE 20030760 A1 PE20030760 A1 PE 20030760A1 PE 2002001190 A PE2002001190 A PE 2002001190A PE 2002001190 A PE2002001190 A PE 2002001190A PE 20030760 A1 PE20030760 A1 PE 20030760A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- cellular growth
- erbb2
- methyl
- abnormal cellular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A UN INHIBIDOR DE erbB2 DE MOLECULA PEQUENA QUE PRESENTA UN INTERVALO DE SELECTIVIDAD POR erbB2 RESPECTO A erbB1 ENTRE 50-1500 Y UNA CI50 MENOR A 50nM. EL INHIBIDOR DE erbB2 SE SELECCIONA DE N-{3-[4-(5-METIL-6-FENOXIPIRIDIN-3-ILAMINO)-QUINAZOLIN-6-IL]-PROP-2-INIL}-2-OXO-PROPIONAMIDA, (3-4{4-[3-METIL-4-(PIRIDIN-3-ILOXI)-FENILAMINO]-QUINAZOLIN-6-IL]-AMINA DEL ACIDO CICLOPROPANOCARBOXILICO, 2-METOXI-N-(3-{4-(4-(3-METOXIFENOXI)-3-METIL-FENILAMINO)-QUINAZOLIN-6-IL}-PROP-2-INIL)-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS SON UTILES EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34109101P | 2001-12-12 | 2001-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030760A1 true PE20030760A1 (es) | 2003-09-05 |
Family
ID=23336198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002001190A PE20030760A1 (es) | 2001-12-12 | 2002-12-10 | Moleculas pequenas para el tratamiento del crecimiento celular anormal |
Country Status (29)
Country | Link |
---|---|
US (1) | US20030171386A1 (es) |
EP (1) | EP1465632A1 (es) |
JP (1) | JP4181502B2 (es) |
KR (1) | KR20040063948A (es) |
CN (1) | CN1602195A (es) |
AP (1) | AP2004003058A0 (es) |
AR (1) | AR037771A1 (es) |
AU (1) | AU2002339687A1 (es) |
BR (1) | BR0214499A (es) |
CA (1) | CA2469670A1 (es) |
DO (1) | DOP2002000545A (es) |
EA (1) | EA200400680A1 (es) |
EC (1) | ECSP045146A (es) |
GT (1) | GT200200273A (es) |
HR (1) | HRP20040529A2 (es) |
HU (1) | HUP0501069A2 (es) |
IL (1) | IL161908A0 (es) |
IS (1) | IS7233A (es) |
MA (1) | MA27154A1 (es) |
MX (1) | MXPA04004107A (es) |
NO (1) | NO20042882L (es) |
OA (1) | OA12734A (es) |
PA (1) | PA8561301A1 (es) |
PE (1) | PE20030760A1 (es) |
PL (1) | PL373848A1 (es) |
TN (1) | TNSN04111A1 (es) |
TW (1) | TW200301121A (es) |
WO (1) | WO2003049740A1 (es) |
ZA (1) | ZA200404264B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
JP4703183B2 (ja) * | 2002-07-15 | 2011-06-15 | シンフォニー エボルーション, インク. | 受容体型キナーゼモジュレーターおよびその使用方法 |
JP2006513179A (ja) * | 2002-12-18 | 2006-04-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療のための4−アニリノキナゾリン誘導体 |
EP1575936A1 (en) * | 2002-12-19 | 2005-09-21 | Pfizer Products Inc. | Complexes of e-2-methoxy-n-(3-{4- [3-methyl-4-(6-methyl- pyridin -3-yloxy)-phenylamino] -quinazolin-6-yl}-allyl)-acetamide, their method of production, and use |
CA2536140A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
PL2213661T3 (pl) | 2003-09-26 | 2011-12-30 | Exelixis Inc | Modulatory c-Met i sposoby ich zastosowania |
EP1708712A1 (en) * | 2003-12-24 | 2006-10-11 | Scios, Inc. | Treatment of malignant gliomas with tgf-beta inhibitors |
NZ550796A (en) * | 2004-05-06 | 2010-07-30 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
GB0417107D0 (en) * | 2004-07-30 | 2004-09-01 | Wellcome Trust The | Genes II |
JP2008542356A (ja) * | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 異常な細胞増殖の治療用の二環式誘導体 |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
JPWO2008072634A1 (ja) | 2006-12-12 | 2010-04-02 | 武田薬品工業株式会社 | 縮合複素環化合物 |
KR20090116782A (ko) | 2007-02-06 | 2009-11-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법 |
MY150290A (en) | 2008-02-07 | 2013-12-31 | Boehringer Ingelheim Int | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
TW200944528A (en) | 2008-03-12 | 2009-11-01 | Takeda Pharmaceutical | Fused heterocyclic compound |
AU2009247782C1 (en) | 2008-05-13 | 2013-09-19 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline |
WO2010015522A1 (de) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
JP5677318B2 (ja) | 2009-01-16 | 2015-02-25 | エクセリクシス, インク. | N−(4−{[6,7−ビス(メチルオキシ)キノリン−4−イル]オキシ}フェニル)−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドのリンゴ酸塩およびその結晶質形態 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
US9265739B2 (en) | 2010-06-02 | 2016-02-23 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to HER2/neu receptor complex |
US8993634B2 (en) | 2010-06-02 | 2015-03-31 | The Trustees Of The University Of Pennsylvania | Methods and use of compounds that bind to Her2/neu receptor complex |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US20130084286A1 (en) | 2011-08-31 | 2013-04-04 | Thomas E. Januario | Diagnostic markers |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
KR101589632B1 (ko) | 2014-06-03 | 2016-02-01 | 한국과학기술연구원 | 항암활성을 가지는 6-벤질옥시퀴나졸린-7-일유레아 유도체 |
CN107922609B (zh) | 2015-07-01 | 2020-04-24 | 加州理工学院 | 基于阳离子粘酸聚合物的递送系统 |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
CA3099440A1 (en) | 2018-06-13 | 2019-12-19 | California Institute Of Technology | Nanoparticles for crossing the blood brain barrier and methods of treatment using the same |
JP2023512175A (ja) * | 2020-02-03 | 2023-03-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | HER2阻害薬としての[1,3]ジアジノ[5,4-d]ピリミジン |
US20230126204A1 (en) | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
CN113429390B (zh) * | 2020-03-23 | 2022-04-15 | 苏州恩华生物医药科技有限公司 | 喹唑啉衍生物及其应用 |
US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
EP1192151B1 (en) * | 1999-07-09 | 2007-11-07 | Glaxo Group Limited | Anilinoquinazolines as protein tyrosine kinase inhibitors |
SK286628B6 (sk) * | 1999-10-19 | 2009-02-05 | Merck & Co., Inc. | Inhibítory tyrozín-kinázy, farmaceutický prostriedok s ich obsahom a ich použitie |
EA005525B1 (ru) * | 2000-06-22 | 2005-04-28 | Пфайзер Продактс Инк. | Замещенные бициклические производные для лечения аномального роста клеток |
MXPA04005678A (es) * | 2001-12-12 | 2004-12-06 | Pfizer Prod Inc | Formas de sal de e-2 -metoxi -n- (3- (4- (3-metil -piridin-3- iloxil ) fenilamino) quinazolin -6-il) alil) alil) acetamida, su preparacion y su uso contra el cancer. |
-
2002
- 2002-11-04 BR BR0214499-9A patent/BR0214499A/pt not_active IP Right Cessation
- 2002-11-04 AU AU2002339687A patent/AU2002339687A1/en not_active Abandoned
- 2002-11-04 CN CNA028237293A patent/CN1602195A/zh active Pending
- 2002-11-04 CA CA002469670A patent/CA2469670A1/en not_active Abandoned
- 2002-11-04 KR KR10-2004-7009022A patent/KR20040063948A/ko not_active Application Discontinuation
- 2002-11-04 JP JP2003550789A patent/JP4181502B2/ja not_active Expired - Fee Related
- 2002-11-04 PL PL02373848A patent/PL373848A1/xx not_active Application Discontinuation
- 2002-11-04 MX MXPA04004107A patent/MXPA04004107A/es not_active Application Discontinuation
- 2002-11-04 WO PCT/IB2002/004636 patent/WO2003049740A1/en active Application Filing
- 2002-11-04 EA EA200400680A patent/EA200400680A1/ru unknown
- 2002-11-04 OA OA1200400160A patent/OA12734A/en unknown
- 2002-11-04 EP EP02777736A patent/EP1465632A1/en not_active Withdrawn
- 2002-11-04 HU HU0501069A patent/HUP0501069A2/hu unknown
- 2002-11-04 AP APAP/P/2004/003058A patent/AP2004003058A0/en unknown
- 2002-11-04 IL IL16190802A patent/IL161908A0/xx unknown
- 2002-12-10 TW TW091135662A patent/TW200301121A/zh unknown
- 2002-12-10 PE PE2002001190A patent/PE20030760A1/es not_active Application Discontinuation
- 2002-12-10 DO DO2002000545A patent/DOP2002000545A/es unknown
- 2002-12-10 AR ARP020104778A patent/AR037771A1/es unknown
- 2002-12-10 US US10/315,863 patent/US20030171386A1/en not_active Abandoned
- 2002-12-12 GT GT200200273A patent/GT200200273A/es unknown
- 2002-12-12 PA PA20028561301A patent/PA8561301A1/es unknown
-
2004
- 2004-04-26 IS IS7233A patent/IS7233A/is unknown
- 2004-05-31 ZA ZA200404264A patent/ZA200404264B/en unknown
- 2004-06-08 MA MA27731A patent/MA27154A1/fr unknown
- 2004-06-09 HR HR20040529A patent/HRP20040529A2/hr not_active Application Discontinuation
- 2004-06-10 EC EC2004005146A patent/ECSP045146A/es unknown
- 2004-06-11 TN TNP2004000111A patent/TNSN04111A1/fr unknown
- 2004-07-07 NO NO20042882A patent/NO20042882L/no unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP045146A (es) | 2004-07-23 |
EA200400680A1 (ru) | 2005-06-30 |
PL373848A1 (en) | 2005-09-19 |
US20030171386A1 (en) | 2003-09-11 |
BR0214499A (pt) | 2005-05-10 |
GT200200273A (es) | 2003-10-03 |
KR20040063948A (ko) | 2004-07-14 |
OA12734A (en) | 2006-06-28 |
AU2002339687A1 (en) | 2003-06-23 |
IL161908A0 (en) | 2005-11-20 |
AP2004003058A0 (en) | 2004-06-30 |
IS7233A (is) | 2004-04-26 |
TNSN04111A1 (fr) | 2006-06-01 |
CN1602195A (zh) | 2005-03-30 |
TW200301121A (en) | 2003-07-01 |
HUP0501069A2 (en) | 2006-06-28 |
AR037771A1 (es) | 2004-12-01 |
CA2469670A1 (en) | 2003-06-19 |
EP1465632A1 (en) | 2004-10-13 |
MXPA04004107A (es) | 2004-07-23 |
JP4181502B2 (ja) | 2008-11-19 |
HRP20040529A2 (en) | 2004-10-31 |
MA27154A1 (fr) | 2005-01-03 |
ZA200404264B (en) | 2005-08-31 |
WO2003049740A1 (en) | 2003-06-19 |
PA8561301A1 (es) | 2003-12-30 |
DOP2002000545A (es) | 2003-06-16 |
NO20042882L (no) | 2004-07-07 |
JP2005527486A (ja) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030760A1 (es) | Moleculas pequenas para el tratamiento del crecimiento celular anormal | |
PE20050598A1 (es) | Compuestos moduladores de cb1 | |
PE20050229A1 (es) | Derivados de etinilprolina | |
ME00353B (me) | 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji | |
PE20091901A1 (es) | Activadores de glucoquinasa | |
MX2007005408A (es) | Compuestos de aminoquinazolinas. | |
PE20211375A1 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
HRP20050352B1 (hr) | Piperazinilni i diazepanilni benzamidi i benztioamidi | |
PE20070490A1 (es) | Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 | |
UY26291A1 (es) | Compuestos químicos xxii | |
ECSP055747A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
PE20010070A1 (es) | COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2 | |
PE20030238A1 (es) | Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales | |
ECSP055746A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
PE20110581A1 (es) | Compuestos pirazina como inhibidores de fosfodiesterasa 10 | |
ATE420866T1 (de) | 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
CO5700779A2 (es) | Un proceso para la preparación de oxi-(1h)-quinolin-2-onas 5-(haloacetil)-8-sustituidas | |
PE20050342A1 (es) | Tableta que contiene el ester etilico de acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino]-propionico o sus sales | |
PE20010913A1 (es) | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2-sustituidas | |
TR200403020T2 (tr) | (S)-4-Amino-5-kloro-2-metoksi-N- (1-(1-(2-tetrahidrofuril-carbonil)-4-piperidinylmetil) -4-piperidinil)benzamit, bunun hazırlama işlemi ve aynı formülü ve bunun ara mamülünü içeren farmasötik bileşim | |
MA32818B1 (fr) | Arylpiperazines et leur emploi en tant qu'antagonistes de alpha2c | |
ECSP045219A (es) | Derivados de quinazolinona y su uso como agonistas cb | |
PE20061363A1 (es) | Derivados de 4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina como agonistas del receptor fsh |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |